BACKGROUND Guidelines for primary prevention of cardiovascular disease provide little guidance on how patients' preferences should be taken into account. We wanted to explore whether general practitioners (GPs) are sensitive to patient preferences regarding survival gains from statin therapy. METHODS In a cross sectional, online survey 3,270 Norwegian GPs were presented with a 55 year old pat...

BACKGROUND AND PURPOSE The use of ± 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') is associated with cardiovascular complications and hyperthermia. EXPERIMENTAL APPROACH We assessed the effects of the α(1) - and β-adrenoceptor antagonist carvedilol on the cardiostimulant, thermogenic and subjective responses to MDMA in 16 healthy subjects. Carvedilol (50 mg) or placebo was administered ...

INTRODUCTION Various prescribed and over-the-counter medications may theoretically be incompatible with the diving environment. Anecdotally, it is known divers regularly take medications around the time of their diving activities for different health conditions, possibly ignoring the recommendations not to do so. As part of a diversion in a study of illicit drug use in sport divers, secondary d...

Type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and the cardiovascular effect of antidiabetic drugs are today critical medical issues, with the prevalence of T2DM in particular showing a steep increase worldwide, mainly due to unhealthy lifestyle habits. T2DM in association with obesity and other cardiovascular risk factors, results in the development of CVD, the leading cause of ...

Type 2 diabetes mellitus is an independent risk factor for Cardiovascular Disease (CVD) and hypertension and patients with Type2 DM has a two-to four fold risk in developing CVD than nondiabetic persons [1]. For very long time, management of Type2 DM was focused on controlling blood glucose, since hyperglycemia has been associated with increased cardiovascular risk [2,3], but aggressive blood g...

This paper contributes to a small but growing body of evidence regarding the efficacy of value-based insurance design. In a retrospective, observational study of employees of a large global pharmaceutical firm, we evaluated how reduced patient cost sharing for prescription drugs for asthma, hypertension, and diabetes affected the use of these drugs and related medical services. We estimate that...

background and aims: diabetic nephropathy (dn) is the most common cause of end-stage renal failure which could increase the risk of cardiovascular disease and morbidity and mortality in patients. the aim of this study was to investigate new modalities for treatment of diabetic nephropathy. methods:this study was a mini-review research to investigate drugs that are used for dn treatment. results...

In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials...

OBJECTIVE To investigate whether there is an increased risk of cardiovascular events in people who exhibit iatrogenic Cushing's syndrome during treatment with glucocorticoids. DESIGN Cohort study. SETTING 424 UK general practices contributing to The Health Improvement Network database. PARTICIPANTS People prescribed systemic glucocorticoids and with a diagnosis of iatrogenic Cushing's syn...